thumb
July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
July 8, 2021

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S.

thumb
June 25, 2021

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™

INCHEON, Korea and CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ™, a biosimilar

thumb
June 23, 2021

EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass, – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough

thumb
June 23, 2021

Biogen and Eisai Update for the Alzheimer’s Disease Community

CAMBRIDGE, Mass. and WOODCLIFF LAKE, N.J., June 23, 2021 – Biogen (Nasdaq: BIIB) and Eisai Inc., U.S. subsidiary of Eisai Co., Ltd. today issued the following statement: On June 7, 2021, ADUHELM™ (aducanumab-avwa) 100 mg/mL solution for injection was granted accelerated approval by the U.S. Food and Drug Administration (FDA). We are committed to responding to questions from the Alzheimer’s disease community and providing more details about our plans.

thumb
June 22, 2021

Biogen to Participate in SVB Leerink’s 3rd Annual CNS Forum

Cambridge, MA, - - Biogen Inc .  (Nasdaq: BIIB) announced today that it will participate in SVB Leerink’s 3rd Annual CNS Forum. The webcast will be live on Tuesday, June 29, at 1:50 p.m. ET.  To access the live webcast, please go to the investors section of Biogen’s website at 

thumb
June 17, 2021

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE) , a debilitating autoimmune disease which has limited treatment options Positive Phase 2 LILAC study efficacy results support the further evaluation of

thumb
June 16, 2021

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment for Alzheimer’s disease.

thumb
June 15, 2021

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically meaningful reduction in depressive symptoms as measured by HAMD-17 (p=0.0141) compared to placebo Rapid onset of treatment effect was seen in HAMD-17 results at Days 3, 8, and 12 Patients with a

thumb
June 14, 2021

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

The Phase 3 STAR study did not meet primary or key secondary endpoints Choroideremia is a rare inherited retinal disease that results in progressive vision loss, ultimately leading to blindness CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.

thumb
June 10, 2021

Biogen Announces Investor Day on September 21, 2021

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.   (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies. The event will be webcast live on September 21, 2021 at 10:00 a.m. ET.